PDCD1 and cancer: Consequently, the dual specificity of c-MET BsAbs toward both c-MET on tumor cells and immune cell receptors like CD3 or PD-1 facilitates the mobilization and activation of immune cells to eliminate c-MET-overexpressing tumor cells, thereby amplifying the effectiveness of cancer immunotherapy (16, 89).